Researchers have proposed that TP prostate biopsies be offered an option to all men.
The term "personalized medicine" remains an overused promise to apply specific treatment plans.
Although several biomarkers show promise, PCA3 has garnered substantial attention following FDA approval and its role in the diagnosis of PCa will grow.
Elevated urinary levels of the organic compound were found in men with prostate cancer than in those without it.
It is associated with fewer positive surgical margins and reduced need for additional treatment.
Increasing health insurance coverage and access to usual source of care necessary to meet targets.
In a trial, more patients taking sildenfail citrate than placebo daily had functional erections at 24 months.
Complications other than urinary incontinence or erectile dysfunction occur frequently following treatment for PCa.
Blood loss is reduced and hospital stays are shorter compared with retropubic radical prostatectomy, but oncologic outcomes are similar.
Men who maintain good physical fitness have a lower risk of lung and colorectal cancer.
Prostate cancer patients who undergo RP by a different urologist are less likely to suffer surgical complications.
Compared with standard-dose radiotherapy, higher-dose radiotherapy was associated with better cancer control at 10 years.
High intake appears to be especially protective against lethal PCa, data show.
High PSA and short PSA double time are associated with a greater likelihood of a positive bone scan.
D'Amico criteria incorrectly classified 37.5% of patients as having low-risk disease.
Transperineal technique should be offered as an option because it is associated with less sepsis than the transrectal approach.
Men with prostate cancer on active surveillance should be informed of the risk of complications.
A prostate cancer diagnosis was 54% more likely in men with metabolic syndrome.